Lower-Risk Myelodysplastic Syndromes (LR-MDS): Highlights from EHA 2024 - Episode 7
Treatment Decision-Making Based on the COMMANDS Trials
The panel examines the COMMANDS trial results, focusing on luspatercept's effects across erythroid, neutrophil, and platelet lineages and their implications for treatment decisions, while also exploring how genomic factors and mutational burden influence the drug's clinical outcomes in lower-risk myelodysplastic syndromes.
Video Player is loading.
- How does the COMMANDS trial and outcomes on erythroid, neutrophil, and platelet lineages impact your treatment decision-making?
- How does the genomic landscape and mutational burden impact clinical outcomes of luspatercept from the COMMANDS trial?
Related Content:
